Direct-acting antiviral-induced hepatitis c virus clearance does not completely restore the altered cytokine and chemokine milieu in patients with chronic hepatitis c

Journal of Infectious Diseases

Volumn 214, Issue 12, 2016, Pages 1965-1974

  Hengst, Julia ^a   Falk, Christine Susanne ^b,c,d   Schlaphoff, Verena ^a   Deterding, Katja ^a   Manns, Michael Peter ^a,c,d   Cornberg, Markus ^a,d   Wedemeyer, Heiner ^a,b,c  

^a and Endocrinology ^*  (United States)

^b Institute of Transplant Immunology   (United Kingdom)

^c HANNOVER MEDICAL SCHOOL   (Germany)

^d Center for Experimental and Clinical Infection Research   (Germany)

Author keywords

Chemokines; Chronic hepatitis C; Cirrhosis; Cytokines; DAA; Direct acting antiviral; HCV; Soluble immune mediators

Indexed keywords

ALANINE AMINOTRANSFERASE; ALPHA2 INTERFERON; ANTIVIRUS AGENT; CHEMOKINE; CYTOKINE; GAMMA INTERFERON; GAMMA INTERFERON INDUCIBLE PROTEIN 10; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 12P40; INTERLEUKIN 17; INTERLEUKIN 18; INTERLEUKIN 1BETA; INTERLEUKIN 4; PLATELET DERIVED GROWTH FACTOR; RIBAVIRIN; SOFOSBUVIR; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; VASCULAR CELL ADHESION MOLECULE 1; PROTEINASE INHIBITOR;

ADULT; AGED; CHRONIC HEPATITIS C; CLINICAL ARTICLE; CONFERENCE PAPER; CONTROLLED STUDY; DOWN REGULATION; DRUG EFFICACY; FATTY LIVER; FEMALE; HUMAN; LIVER CIRRHOSIS; LIVER FIBROSIS; LIVER INJURY; MALE; OUTCOME ASSESSMENT; PROTEIN EXPRESSION; RELAPSE; UPREGULATION; VIRAL CLEARANCE; VIRUS REPLICATION; BLOOD; HEPATITIS C, CHRONIC; IMMUNOLOGY; LONGITUDINAL STUDY; MIDDLE AGED; SUSTAINED VIROLOGIC RESPONSE; YOUNG ADULT;

ADULT; AGED; ANTIVIRAL AGENTS; CYTOKINES; FEMALE; HEPATITIS C, CHRONIC; HUMANS; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; PROTEASE INHIBITORS; SUSTAINED VIROLOGIC RESPONSE; YOUNG ADULT;

EID: 85015995928     PISSN: 00221899     EISSN: 15376613     Source Type: Journal    
DOI: 10.1093/infdis/jiw457     Document Type: Conference Paper

References (32)

1. Beltra JC, Decaluwe H. Cytokines and persistent viral infections. Cytokine 2016; 82:4-15.
2. Protzer U, Maini MK, Knolle PA. Living in the liver: hepatic infections. Nat Rev Immunol 2012; 12:201-13.
3. Gower E, Estes C, Blach S, Razavi-Shearer K, Razavi H. Global epidemiology and genotype distribution of the hepatitis C virus infection. J Hepatol 2014; 61: S45-57.
4. Klenerman P, Thimme R. T cell responses in hepatitis C: the good, the bad and the unconventional. Gut 2012; 61:1226-34.
5. Heim MH, Thimme R. Innate and adaptive immune responses in HCV infections. J Hepatol 2014; 61:S14-25.
6. Duffy D, Mamdouh R, Laird M, et al. The ABCs of viral hepatitis that define biomarker signatures of acute viral hepatitis. Hepatology 2014; 59:1273-82.
7. Marra F, Tacke F. Roles for chemokines in liver disease. Gastroenterology 2014; 147:577-94. e1.
8. Owusu Sekyere S, Suneetha PV, Hardtke S, et al. Type I interferon elevates co-regulatory receptor expression on CMV-and EBV-specific CD8T cells in chronic hepatitis C. Front Immunol 2015; 6:270.
9. Golden-Mason L, Waasdorp Hurtado CE, Cheng L, Rosen HR. Hepatitis C viral infection is associated with activated cytolytic natural killer cells expressing high levels of T cell immunoglobulin-and mucin-domain-containing molecule-3. Clin Immunol 2015; 158:114-25.
10. Rehermann B. Pathogenesis of chronic viral hepatitis: differential roles of T cells and NK cells. Nat Med 2013; 19:859-68.
11. Gane EJ, Stedman CA, Hyland RH, et al. Nucleotide polymerase inhibitor sofosbuvir plus ribavirin for hepatitis C. N Engl J Med 2013; 368:34-44.
12. Lawitz E, Mangia A, Wyles D, et al. Sofosbuvir for previously untreated chronic hepatitis C infection. N Engl J Med 2013; 368:1878-87.
13. Foster GR, Irving WL, Cheung MC, et al. Impact of direct acting antiviral therapy in patients with chronic hepatitis C and decompensated cirrhosis. J Hepatol 2016; 64:1224-31.
14. Wiegand J, Cornberg M, Aslan N, et al. Fate and function of hepatitis-C-virus-specific T-cells during peginterferon-alpha2b therapy for acute hepatitis C. Antivir Ther 2007; 12:303-16.
15. Barnes E, Harcourt G, Brown D, et al. The dynamics of T-lymphocyte responses during combination therapy for chronic hepatitis C virus infection. Hepatology 2002; 36:743-54.
16. Missale G, Pilli M, Zerbini A, et al. Lack of full CD8 functional restoration after antiviral treatment for acute and chronic hepatitis C virus infection. Gut 2012; 61:1076-84.
17. Jablonska J, Pawlowski T, Laskus T, et al. The correlation between pretreatment cytokine expression patterns in peripheral blood mononuclear cells with chronic hepatitis C outcome. BMC Infect Dis 2015; 15:556.
18. Carlin AF, Aristizabal P, Song Q, et al. Temporal dynamics of inflammatory cytokines/ chemokines during sofosbuvir and ribavirin therapy for genotype 2 and 3 hepatitis C infection. Hepatology 2015; 62:1047-58.
19. Wandrer F, Falk CS, John K, et al. Interferon-mediated cytokine induction determines sustained virus control in chronic hepatitis C virus Infection. J Infect Dis 2016; 213:746-54.
20. Deterding K, Honer Zu Siederdissen C, Port K, et al. Improvement of liver function parameters in advanced HCV-associated liver cirrhosis by IFN-free antiviral therapies. Aliment Pharmacol Ther 2015; 42:889-901.
21. Wranke A, Heidrich B, Ernst S, et al. Anti-HDV IgM as a marker of disease activity in hepatitis delta. PLoS One 2014; 9:e101002.
22. Gisa A, Suneetha PV, Behrendt P, et al. Cross-genotype-specific T-cell responses in acute hepatitis E virus (HEV) infection. J Viral Hepat 2016; 23:305-15.
23. Lemke A, Noriega M, Roske AM, et al. Rat renal transplant model for mixed acute humoral and cellular rejection: weak correlation of serum cytokines/chemokines with intragraft changes. Transpl Immunol 2015; 33:95-102.
24. Hammerich L, Tacke F. Interleukins in chronic liver disease: lessons learned from experimental mouse models. Clin Exp Gastroenterol 2014; 7:297-306.
25. Williams MJ, Clouston AD, Forbes SJ. Links between hepatic fibrosis, ductular reaction, and progenitor cell expansion. Gastroenterology 2014; 146:349-56.
26. Patel K, Remlinger KS, Walker TG, et al. Multiplex protein analysis to determine fibrosis stage and progression in patients with chronic hepatitis C. Clin Gastroenterol Hepatol 2014; 12:2113-20. e1-3.
27. Rehermann B, Bertoletti A. Immunological aspects of antiviral therapy of chronic hepatitis B virus and hepatitis C virus infections. Hepatology 2015; 61:712-21.
28. Meissner EG, Wu D, Osinusi A, et al. Endogenous intrahepatic IFNs and association with IFN-free HCV treatment outcome. J Clin Invest 2014; 124:3352-63.
29. Klatt NR, Chomont N, Douek DC, Deeks SG. Immune activation and HIV persistence: implications for curative approaches to HIV infection. Immunol Rev 2013; 254:326-42.
30. Hengst J, Strunz B, Deterding K, et al. Nonreversible MAIT cell-dysfunction in chronic hepatitis C virus infection despite successful interferon-free therapy. Eur J Immunol 2016; 46:2204-10.
31. Spaan M, Hullegie SJ, Beudeker BJ, et al. Frequencies of circulating MAIT cells are diminished in chronic HCV, HIV and HCV/HIV co-infection and do not recover during therapy. PLoS One 2016; 11:e0159243.
32. Deterding K, Schlevogt B, Port K, Cornberg M,Wedemeyer H. Letter: can persisting liver stiffness indicate increased risk of hepatocellular cell carcinoma after successful anti-HCV therapy?-authors' reply. Aliment Pharmacol Ther 2016; 43:546-7.